ProMIS Neurosciences (PMN) Institutional Ownership $0.99 +0.10 (+11.11%) As of 03:59 PM Eastern Add Compare Share Share Ownership Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for ProMIS Neurosciences (NASDAQ:PMN)CurrentInstitutional OwnershipPercentage50.13%Number ofInstitutional Buyers(last 12 months)3TotalInstitutional Inflows(last 12 months)$4.30MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$9.65K Get PMN Insider Trade Alerts Want to know when executives and insiders are buying or selling ProMIS Neurosciences stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data PMN Institutional Buying and Selling by Quarter ProMIS Neurosciences Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/15/2024Sphera Funds Management LTD.1,929,297$2.41M0.4%+6.3%6.455% 11/14/2024Ally Bridge Group NY LLC1,592,605$1.99M1.1%+50.3%5.328% 11/13/2024Great Point Partners LLC2,790,698$3.49M1.0%N/A9.337% 2/7/2024Ieq Capital LLC30,799$35K0.0%-21.4%0.163% 11/15/2023Affinity Asset Advisors LLC265,958$527K0.1%N/A3.100% 11/15/2022Northeast Financial Consultants Inc100,000$613K0.0%N/A1.166% 11/4/2022Ieq Capital LLC39,191$240K0.0%N/A0.457% (Data available from 1/1/2016 forward) PMN Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of PMN shares? During the previous two years, the following institutional investors and hedge funds held shares of ProMIS Neurosciences shares: Great Point Partners LLC ($3.49M), Sphera Funds Management LTD. ($2.41M), Ally Bridge Group NY LLC ($1.99M), and Affinity Asset Advisors LLC ($527K), Ieq Capital LLC ($35K).Learn more on PMN's institutional investors. What percentage of ProMIS Neurosciences stock is owned by institutional investors? 50.13% of ProMIS Neurosciences stock is owned by institutional investors. Learn more on PMN's institutional investor holdings. Which institutional investors have been buying ProMIS Neurosciences stock? The following institutional investors have purchased ProMIS Neurosciences stock in the last 24 months: Great Point Partners LLC ($2.79M), Ally Bridge Group NY LLC ($533.02K), Affinity Asset Advisors LLC ($265.96K), and Sphera Funds Management LTD. ($115.08K). How much institutional buying is happening at ProMIS Neurosciences? Institutional investors have bought a total of 3,704,763 shares in the last 24 months. This purchase volume represents approximately $4.83M in transactions. Which ProMIS Neurosciences major shareholders have been selling company stock? The following institutional investors have sold ProMIS Neurosciences stock in the last 24 months: Ieq Capital LLC ($8.39K). How much institutional selling is happening at ProMIS Neurosciences? Institutional investors have sold a total of 8,392 shares in the last 24 months. This volume of shares sold represents approximately $9.65K in transactions. Related Companies Black Diamond Therapeutics Major Shareholders Zura Bio Major Shareholders 2seventy bio Major Shareholders Instil Bio Major Shareholders Aligos Therapeutics Major Shareholders Tenaya Therapeutics Major Shareholders Leap Therapeutics Major Shareholders XBiotech Major Shareholders Atossa Therapeutics Major Shareholders Alto Neuroscience Major Shareholders This page (NASDAQ:PMN) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProMIS Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProMIS Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
